2026 Q2 - tulosraportti
68 päivää sitten
‧31 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
NimiOsuus
DNB Fund Disrpt Opps A EUR Acc
2,97%Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 30.7. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 4.11.2025 | ||
2025 Q2 - tulosraportti 8.8.2025 |
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·29.9.Are we too late here what do people think?
·17.9.article from Barron's: Clarity on how much revenue Tempus AI will receive via Medicare reimbursements for two of its cancer screenings pleased investors this week, causing the stock to rise sharply on Thursday. Tempus stock rose by 15 % on Thursday as part of a 36 % gain over the past five trading days. The stock moved towards its highest closing price since November 5, 2025, when it closed at $82.26. The ARK Innovation ETF fund, where Tempus is the third largest holding after Tesla and SpaceX, rose by 4.3 %. CEO Eric Lefkofsky spoke on Tuesday at Morgan Stanley's Global Healthcare Conference and stated that Tempus expects reimbursements of between $80 million and $100 million next year for its tissue scanning test, as well as between $250 million and $300 million for its liquid biopsy (fluid biopsy). Tempus announced in July that the company is acquiring cancer testing company Personalis for $1.5 billion, with the stated reason that the deal will "strengthen the ability to support patients from diagnosis and treatment selection to recurrence and monitoring". Tempus stated that it is acquiring all outstanding shares in Personalis for $16.25 per share, which is largely being carried out via Tempus shares. The stock briefly dipped after the announcement as Wall Street reacted negatively to the acquisition being financed with shares, but the stock has risen by 92 % since reaching its 52-week low of $41.55 on July 29. Tempus reported $382.5 million in revenue for the second quarter on July 30 and signaled $200 million in new licenses for its data and applications business. The diagnostics segment accounted for 76 % of total revenue. In March, Cathie Wood's ARK Invest bought nearly 85,000 shares in the health-tech company as the fund sold off some of its holdings in Meta.
·17.9.Part of the explanation for the strong rise in Tempus AI recently may be the developments currently taking place in American healthcare policy. The Trump administration is actively working to integrate AI as a larger part of the healthcare system. The ambition is not just AI that writes medical notes, but systems that in the long term can diagnose, follow up on patients, and autonomously perform certain parts of treatment. Here, Tempus is directly involved. On 9. September, the American health research agency ARPA-H selected Tempus as one of the entities to develop an autonomous clinical AI agent for patients with heart failure. Tempus can receive up to 9,5 million dollar for the project. The goal of the larger federal program is to develop a new type of FDA-approved clinical AI that can function as a digital member of the treatment team 24/7. The AI should be able to handle parts of patient follow-up itself and involve healthcare personnel when necessary. What is interesting for Tempus is therefore not the size of the contract. 9,5 million dollar is relatively little for the company. What is interesting is that American authorities have actually chosen Tempus as one of the entities to participate in developing this new model for healthcare. If the development continues from "AI helps the doctor" to "AI performs parts of the doctor's work", the market for companies like Tempus could become enormous. It is simultaneously important to point out that this is still under development, must go through clinical testing and regulatory approval, and that the rise in the Tempus share also has other explanations – including expectations of higher reimbursement revenues and strong business growth.
17.9.Eric Lefkofsky’s Morgan Stanley conference appearance on September 15, 2026: The key comments are: xT: ~$80–100M incremental annual revenue/ASP benefit from ADLT pricing. xF: ~$250–300M annual incremental benefit once approved/priced. He says Medicare/Medicaid reimbursement appears stable and durable. On data licensing, he says they had ~$200M of bookings in the latest quarter and that demand is being accelerated by AI adoption in pharma. He says Tempus has multiple $100M+ long-term data licensing deals with companies including AstraZeneca, BMS, GSK, Merck and BioNTech. And as an icing on the cake: He also explicitly says he expects the business to maintain 25%+ growth, while emphasizing long-term durability. I will not add a rocket emoji, but I'm thinking about it 🍀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
68 päivää sitten
‧31 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·29.9.Are we too late here what do people think?
- ·17.9.article from Barron's: Clarity on how much revenue Tempus AI will receive via Medicare reimbursements for two of its cancer screenings pleased investors this week, causing the stock to rise sharply on Thursday. Tempus stock rose by 15 % on Thursday as part of a 36 % gain over the past five trading days. The stock moved towards its highest closing price since November 5, 2025, when it closed at $82.26. The ARK Innovation ETF fund, where Tempus is the third largest holding after Tesla and SpaceX, rose by 4.3 %. CEO Eric Lefkofsky spoke on Tuesday at Morgan Stanley's Global Healthcare Conference and stated that Tempus expects reimbursements of between $80 million and $100 million next year for its tissue scanning test, as well as between $250 million and $300 million for its liquid biopsy (fluid biopsy). Tempus announced in July that the company is acquiring cancer testing company Personalis for $1.5 billion, with the stated reason that the deal will "strengthen the ability to support patients from diagnosis and treatment selection to recurrence and monitoring". Tempus stated that it is acquiring all outstanding shares in Personalis for $16.25 per share, which is largely being carried out via Tempus shares. The stock briefly dipped after the announcement as Wall Street reacted negatively to the acquisition being financed with shares, but the stock has risen by 92 % since reaching its 52-week low of $41.55 on July 29. Tempus reported $382.5 million in revenue for the second quarter on July 30 and signaled $200 million in new licenses for its data and applications business. The diagnostics segment accounted for 76 % of total revenue. In March, Cathie Wood's ARK Invest bought nearly 85,000 shares in the health-tech company as the fund sold off some of its holdings in Meta.
- ·17.9.Part of the explanation for the strong rise in Tempus AI recently may be the developments currently taking place in American healthcare policy. The Trump administration is actively working to integrate AI as a larger part of the healthcare system. The ambition is not just AI that writes medical notes, but systems that in the long term can diagnose, follow up on patients, and autonomously perform certain parts of treatment. Here, Tempus is directly involved. On 9. September, the American health research agency ARPA-H selected Tempus as one of the entities to develop an autonomous clinical AI agent for patients with heart failure. Tempus can receive up to 9,5 million dollar for the project. The goal of the larger federal program is to develop a new type of FDA-approved clinical AI that can function as a digital member of the treatment team 24/7. The AI should be able to handle parts of patient follow-up itself and involve healthcare personnel when necessary. What is interesting for Tempus is therefore not the size of the contract. 9,5 million dollar is relatively little for the company. What is interesting is that American authorities have actually chosen Tempus as one of the entities to participate in developing this new model for healthcare. If the development continues from "AI helps the doctor" to "AI performs parts of the doctor's work", the market for companies like Tempus could become enormous. It is simultaneously important to point out that this is still under development, must go through clinical testing and regulatory approval, and that the rise in the Tempus share also has other explanations – including expectations of higher reimbursement revenues and strong business growth.
- 17.9.Eric Lefkofsky’s Morgan Stanley conference appearance on September 15, 2026: The key comments are: xT: ~$80–100M incremental annual revenue/ASP benefit from ADLT pricing. xF: ~$250–300M annual incremental benefit once approved/priced. He says Medicare/Medicaid reimbursement appears stable and durable. On data licensing, he says they had ~$200M of bookings in the latest quarter and that demand is being accelerated by AI adoption in pharma. He says Tempus has multiple $100M+ long-term data licensing deals with companies including AstraZeneca, BMS, GSK, Merck and BioNTech. And as an icing on the cake: He also explicitly says he expects the business to maintain 25%+ growth, while emphasizing long-term durability. I will not add a rocket emoji, but I'm thinking about it 🍀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
NimiOsuus
DNB Fund Disrpt Opps A EUR Acc
2,97%Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 30.7. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 4.11.2025 | ||
2025 Q2 - tulosraportti 8.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
68 päivää sitten
‧31 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 30.7. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 4.11.2025 | ||
2025 Q2 - tulosraportti 8.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·29.9.Are we too late here what do people think?
- ·17.9.article from Barron's: Clarity on how much revenue Tempus AI will receive via Medicare reimbursements for two of its cancer screenings pleased investors this week, causing the stock to rise sharply on Thursday. Tempus stock rose by 15 % on Thursday as part of a 36 % gain over the past five trading days. The stock moved towards its highest closing price since November 5, 2025, when it closed at $82.26. The ARK Innovation ETF fund, where Tempus is the third largest holding after Tesla and SpaceX, rose by 4.3 %. CEO Eric Lefkofsky spoke on Tuesday at Morgan Stanley's Global Healthcare Conference and stated that Tempus expects reimbursements of between $80 million and $100 million next year for its tissue scanning test, as well as between $250 million and $300 million for its liquid biopsy (fluid biopsy). Tempus announced in July that the company is acquiring cancer testing company Personalis for $1.5 billion, with the stated reason that the deal will "strengthen the ability to support patients from diagnosis and treatment selection to recurrence and monitoring". Tempus stated that it is acquiring all outstanding shares in Personalis for $16.25 per share, which is largely being carried out via Tempus shares. The stock briefly dipped after the announcement as Wall Street reacted negatively to the acquisition being financed with shares, but the stock has risen by 92 % since reaching its 52-week low of $41.55 on July 29. Tempus reported $382.5 million in revenue for the second quarter on July 30 and signaled $200 million in new licenses for its data and applications business. The diagnostics segment accounted for 76 % of total revenue. In March, Cathie Wood's ARK Invest bought nearly 85,000 shares in the health-tech company as the fund sold off some of its holdings in Meta.
- ·17.9.Part of the explanation for the strong rise in Tempus AI recently may be the developments currently taking place in American healthcare policy. The Trump administration is actively working to integrate AI as a larger part of the healthcare system. The ambition is not just AI that writes medical notes, but systems that in the long term can diagnose, follow up on patients, and autonomously perform certain parts of treatment. Here, Tempus is directly involved. On 9. September, the American health research agency ARPA-H selected Tempus as one of the entities to develop an autonomous clinical AI agent for patients with heart failure. Tempus can receive up to 9,5 million dollar for the project. The goal of the larger federal program is to develop a new type of FDA-approved clinical AI that can function as a digital member of the treatment team 24/7. The AI should be able to handle parts of patient follow-up itself and involve healthcare personnel when necessary. What is interesting for Tempus is therefore not the size of the contract. 9,5 million dollar is relatively little for the company. What is interesting is that American authorities have actually chosen Tempus as one of the entities to participate in developing this new model for healthcare. If the development continues from "AI helps the doctor" to "AI performs parts of the doctor's work", the market for companies like Tempus could become enormous. It is simultaneously important to point out that this is still under development, must go through clinical testing and regulatory approval, and that the rise in the Tempus share also has other explanations – including expectations of higher reimbursement revenues and strong business growth.
- 17.9.Eric Lefkofsky’s Morgan Stanley conference appearance on September 15, 2026: The key comments are: xT: ~$80–100M incremental annual revenue/ASP benefit from ADLT pricing. xF: ~$250–300M annual incremental benefit once approved/priced. He says Medicare/Medicaid reimbursement appears stable and durable. On data licensing, he says they had ~$200M of bookings in the latest quarter and that demand is being accelerated by AI adoption in pharma. He says Tempus has multiple $100M+ long-term data licensing deals with companies including AstraZeneca, BMS, GSK, Merck and BioNTech. And as an icing on the cake: He also explicitly says he expects the business to maintain 25%+ growth, while emphasizing long-term durability. I will not add a rocket emoji, but I'm thinking about it 🍀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
NimiOsuus
DNB Fund Disrpt Opps A EUR Acc
2,97%Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt